# Dual-target PSMA/PSCA CAR-NK Cells in Advanced Prostate Cancer

> **NCT07641049** · PHASE1 · RECRUITING · sponsor: **Beijing Biotech** · enrollment: 36 (estimated)

## Conditions studied

- Metastatic Castration-resistant Prostate Cancer
- Advanced Prostate Adenocarcinoma
- PSCA-positive Prostate Cancer
- PSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer

## Interventions

- **BIOLOGICAL:** ETB-DualNK-01
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT07641049
- **Lead sponsor:** Beijing Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-02
- **Primary completion:** 2027-03-14
- **Final completion:** 2028-06-17
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07641049

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07641049, "Dual-target PSMA/PSCA CAR-NK Cells in Advanced Prostate Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07641049. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*